CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
Authors
Keywords
-
Journal
CLINICAL INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-07-25
DOI
10.1093/cid/ciaa1073
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy
- (2019) Kassem Bourgi et al. CLINICAL INFECTIOUS DISEASES
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
- (2019) NEW ENGLAND JOURNAL OF MEDICINE
- NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4
- (2018) James E Bennett et al. LANCET
- Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada
- (2016) John R. Koethe et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines
- (2016) Ricardo Moure et al. ANTIVIRAL RESEARCH
- Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen
- (2016) Johannes P. Mouton et al. Expert Review of Clinical Pharmacology
- Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa
- (2015) Phumla Z. Sinxadi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Isoniazid Mediates theCYP2B6*6Genotype-Dependent Interaction between Efavirenz and Antituberculosis Drug Therapy through Mechanism-Based Inactivation of CYP2A6
- (2014) Michael H. Court et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype
- (2013) Helen M. McIlleron et al. AIDS
- Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug Reaction
- (2013) Reneé de Waal et al. PLoS One
- Dual-Energy X-Ray Performs as Well as Clinical Computed Tomography for the Measurement of Visceral Fat
- (2012) Lisa K. Micklesfield et al. Obesity
- Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
- (2012) Emily R. Holzinger et al. Pharmacogenetics and Genomics
- Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy
- (2011) Nadezda Apostolova et al. HEPATOLOGY
- Differential Effects of Efavirenz and Lopinavir/Ritonavir on Human Adipocyte Differentiation, Gene Expression and Release of Adipokines and Pro-Inflammatory Cytokines.
- (2010) Jose M. Gallego-Escuredo et al. CURRENT HIV RESEARCH
- A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
- (2009) Jackson K. Mukonzo et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now